# Comparative safety of cholinesterase inhibitors and memantine for dementia: a protocol for a network meta-analysis of randomized controlled trials

## TL;DR

This study will compare the safety of different dementia medications using data from clinical trials to help guide treatment decisions.

## Contribution

A new network meta-analysis protocol to evaluate safety profiles of cholinesterase inhibitors and memantine across doses and formulations.

## Key findings

- Will assess adverse events, serious adverse events, and treatment discontinuation rates.
- Aims to compare safety across different dementia types and drug formulations.
- Will use a comprehensive literature search and standardized data extraction methods.

## Abstract

Dementia is a growing public health concern, affecting over 55 million people worldwide, with Alzheimer’s disease (AD) being the most prevalent cause. Cholinesterase inhibitors (ChEIs) and memantine remain the mainstay pharmacological treatment for AD and other dementias, despite their modest benefits and potential adverse effects. The safety profiles of these medications, particularly at different doses and formulations, remain inadequately explored, necessitating a comprehensive evaluation.

This systematic review and network meta-analysis (NMA) will assess the safety of ChEIs (donepezil, galantamine, rivastigmine) and memantine in dementia treatment. We will include randomized controlled trials (RCTs) with ≥ 3 months of follow-up, evaluating adverse events (AEs), serious adverse events (SAEs), and treatment discontinuation rates. A comprehensive literature search will be conducted in PubMed, Scopus, Web of Science, and Cochrane Library, with additional searches in Google Scholar and reference lists of included studies.

Data extraction will follow a standardized approach, and study quality will be assessed using the Cochrane risk-of-bias tool-2. A Frequentist or Bayesian NMA framework will be used to compare safety profiles, with heterogeneity assessed using the I2 test.

By addressing gaps in prior NMAs, this study aims to provide an in-depth evaluation of safety outcomes associated with different ChEI and memantine doses and formulations across various dementia types. The findings will support clinicians in making informed treatment decisions and guide future research and policy development for dementia management.

PROSPERO (CRD42025642902).

The online version contains supplementary material available at 10.1186/s13643-025-02961-6.